FF305 第 1 頁 共 8 頁 v 1.3.0 | 1). | 購回股份 (擬註銷但尚未註銷) | | 100,000 | 0.0424 % | HKD | 33.5652 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2025年9月1日 | | | | | | 2). | 購回股份（擬註銷但尚未註銷） | | 140,900 | 0.0597 % | HKD | 33.0529 | | | 變動日期 | 2025年9月2日 | | | | | | 3). | 購回股份（擬註銷但尚未註銷） | | 51,400 | 0.0218 % | HKD | 32.9654 | | | 變動日期 | 2025年9月4日 | | | | | | 4). | 購回股份（擬註銷但尚未註銷） | | 80,200 | 0.0340 % | HKD | 33.5761 | | | 變動日期 | 2025年9月10日 | | | | | | 5). | 購回股份（擬註銷但尚未註銷） | | 74,400 | 0.0315 % | HKD | 33.2982 | ...

Summary of Key Points Core Viewpoint - Multiple companies, including Tencent Holdings and Anta Sports, conducted share buybacks on September 25, 2025, with Tencent leading in both the number of shares repurchased and the total amount spent [1]. Company Buyback Details - Tencent Holdings (00700) repurchased 844,000 shares for a total of 550 million, with a year-to-date total of 63.29 million shares, representing 0.689% of its total share capital [2]. - Anta Sports (02020) repurchased 1.065 million shares for 99.82 million, with a year-to-date total of 7.31 million shares, accounting for 0.260% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 8.1 million shares for 32.97 million, with a year-to-date total of 92.44 million shares, representing 0.080% of its total share capital [2]. - China Hongqiao Group (01378) repurchased 1 million shares for 24.87 million, with a year-to-date total of 153 million shares, accounting for 1.630% of its total share capital [2]. - CIMC (02039) repurchased 3.04 million shares for 23.37 million, with a year-to-date total of 24.78 million shares, representing 0.800% of its total share capital [2]. - Hang Seng Bank (00011) repurchased 200,000 shares for 23.13 million, with a year-to-date total of 7.93 million shares, accounting for 0.421% of its total share capital [2]. - MGM China (02282) repurchased 1 million shares for 15.75 million, with a year-to-date total of 2.58 million shares, representing 0.680% of its total share capital [2]. - Haier Smart Home (06690) repurchased 600,000 shares for 15.17 million, with a year-to-date total of 1.65 million shares, accounting for 0.058% of its total share capital [2]. - Other companies such as Coolpad Group (02369) and Xinyi International (00732) also engaged in buybacks, with Coolpad repurchasing 1.088 million shares for 1.38 million, representing 7.166% of its total share capital [2].

Core Viewpoint - The company achieved revenue of 1.49 billion yuan in H1 2025, a year-on-year increase of 9.5%, and a net profit attributable to shareholders of 150 million yuan, up 41.9% year-on-year, with operating cash flow of 300 million yuan, an increase of 111% year-on-year, and free cash flow of 210 million yuan, up 466% year-on-year [1] Group 1: Financial Performance - The company's revenue from healthcare solutions reached 1.48 billion yuan in H1 2025, a year-on-year increase of 10.4% [1] - Revenue from the sales of health products was 10 million yuan, a decrease of 50.9% year-on-year, primarily due to a reduction in low-margin product sales [1] - Offline institutional revenue was 1.37 billion yuan, a year-on-year increase of 11.1%, with same-store sales accounting for 97.3% of this revenue, indicating growth driven by existing store operations [1] Group 2: Strategic Developments - The company added 7 new stores in H1 2025 (4 self-built and 3 acquired) and entered 2 new cities, indicating a strategy of "steady growth from existing stores and orderly expansion of new stores" [1] - The company reported a 209% year-on-year increase in revenue from in-hospital preparations and other self-priced products, marking explosive growth [2] - The company has established deep collaborations with major platforms like Xiaohongshu, Meituan, Douyin, and Gaode Map, with new users from these platforms accounting for 7.6% of the group's offline new user count [2] Group 3: Future Outlook - The company aims to enhance its AI capabilities, with the AI prescription payment rate reaching 76.7%, showing a month-on-month improvement [2] - The company has accumulated over 20 million consultation data, 18 million cases, and 100,000 high-quality expert data, indicating a strong data foundation for future AI applications [2] - The company plans to open AI-related functions to young doctors in October, further expanding its AI product offerings [2] Group 4: Earnings Forecast - Based on the mid-year report for 2025, the company adjusted its revenue downwards but raised its gross margin forecast, with projected earnings per share for 2025-2027 being 1.54, 1.88, and 2.30 yuan respectively [3] - The company is assigned a target price of 45.54 HKD based on a 27 times price-to-earnings ratio for 2025, maintaining a "buy" rating [3]

Core Viewpoint - The company Guoshengtang has been actively repurchasing its shares, indicating a strategy to support its stock price amid a recent decline in share value [2]. Summary by Category Share Buyback Activity - On September 25, Guoshengtang repurchased 140,000 shares at a price range of HKD 31.140 to HKD 31.520, totaling HKD 4.3815 million [2]. - Since September 10, the company has conducted share buybacks for 12 consecutive days, acquiring a total of 1.3272 million shares for a cumulative amount of HKD 43.1872 million [2]. - The stock has experienced a cumulative decline of 6.52% during the buyback period [2]. - Year-to-date, the company has executed 35 buybacks, totaling 4.2818 million shares and an aggregate amount of HKD 138 million [2]. Detailed Buyback Data - The buyback details include various dates, number of shares repurchased, highest and lowest prices, and total amounts spent, showcasing a consistent effort to stabilize the stock price [3]. - For instance, on September 24, 15,000 shares were repurchased at a maximum price of HKD 31.620, amounting to HKD 4.7004 million [3]. - The highest recorded buyback price was HKD 37.950 on June 5, with a total expenditure of HKD 1.1385 million for 3,000 shares [3].

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The adjustment of medical insurance and commercial insurance directories is accelerating, suggesting a favorable environment for undervalued quality stocks during market corrections [4][5] - The report emphasizes the importance of timing and stock selection in the current market, particularly after a broad rally in innovative drug stocks [4] - The upcoming ESMO conference in October is highlighted as a key event, with specific companies recommended for attention due to potential significant data releases [4] Summary by Sections Market Performance - The Hang Seng Index fell by 1.1% and the Hang Seng Healthcare Index decreased by 1.4% during the week of September 16-23, 2025, ranking 5th among 12 industry indices [4][6] - Sub-industry performance varied, with Internet medicine showing a slight increase of 0.9%, while sectors like medical devices and hospitals saw declines of 5.2% and 8.2%, respectively [4][6] Valuation Overview - The report provides a detailed valuation summary for various companies, with notable price-to-earnings (P/E) ratios for the pharmaceutical sector, such as 31.0x for prescription drugs and 14.1x for biopharmaceuticals [15] - The average P/E ratio across the sector is reported at 57.0, indicating a diverse valuation landscape [3] Institutional Holdings - As of September 23, 2025, domestic institutional holdings through Hong Kong Stock Connect remained stable at 22.2%, while foreign holdings slightly decreased to 38.7% [34][38] - The report notes a trend of increased foreign investment in innovative drug companies, with specific companies like InnoCare and Legend Biotech seeing significant increases in holdings [38][40] Regulatory Developments - The report discusses the recent adjustments to the national basic medical insurance directory and commercial insurance innovative drug directory, with a low approval rate for submitted drugs [5] - The 11th batch of national drug procurement has been announced, with new rules aimed at stabilizing clinical practices and ensuring quality [5]

智通财经APP讯，固生堂(02273)发布公告，于2025年9月25日，该公司斥资438.15万港元回购14万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年9月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02273 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事 ...

Group 1 - The core viewpoint of the reports indicates that Guoshengtang (02273) achieved a revenue of 1.495 billion yuan in H1 2025, representing a year-on-year growth of 9.52%, with a net profit attributable to shareholders of 152 million yuan, reflecting a significant increase of 41.90% [1] - The gross profit margin increased by 1.24 percentage points to 30.63% in H1 2025, indicating improved profitability [1] - The company is projected to generate revenues of 3.513 billion, 4.274 billion, and 5.149 billion yuan from 2025 to 2027, with respective year-on-year growth rates of 16.24%, 21.64%, and 20.47% [1] Group 2 - The revenue from providing healthcare solutions in H1 2025 was 1.48486 billion yuan, up 10.4% year-on-year, accounting for 99.33% of total revenue, primarily driven by growth in offline medical institutions [1] - Revenue from medical health products decreased by 50.9% to 10 million yuan, as the company strategically focused on healthcare solutions, while the gross margin for these products increased to 36.4% [1] - The revenue from offline medical institutions reached 1.36741 billion yuan, marking an 11.1% increase year-on-year, attributed to the growth and increased number of offline medical institutions [1] Group 3 - Guoshengtang launched its first "National Medicine AI Avatar" in June 2025, and by August, it had released 10 AI avatars covering eight core specialties in traditional Chinese medicine [2] - The integration of AI technology into traditional Chinese medicine aims to enhance the supply of quality medical services and address the shortage of quality healthcare resources [2] - The company also introduced an AI health assistant to further improve the patient experience in diagnosis and treatment [2]

Group 1 - The core viewpoint of the report indicates that Guoshengtang (02273) achieved a revenue of 1.495 billion yuan in H1 2025, representing a year-on-year growth of 9.52%, with a net profit attributable to shareholders of 152 million yuan, up 41.90% [1] - The company is expected to generate revenues of 3.513 billion, 4.274 billion, and 5.149 billion yuan from 2025 to 2027, with year-on-year growth rates of 16.24%, 21.64%, and 20.47% respectively [1] - The net profit attributable to shareholders is projected to be 409 million, 542 million, and 687 million yuan for the same period, with growth rates of 33.19%, 32.60%, and 26.80% respectively [1] Group 2 - In H1 2025, the revenue from providing healthcare solutions was 1.48486 billion yuan, a year-on-year increase of 10.4%, accounting for 99.33% of total revenue, primarily due to growth in offline medical institutions [2] - Revenue from the sale of healthcare products decreased by 50.9% to 10 million yuan, as the company strategically focused on providing healthcare solutions [2] - The company launched its first "National Medicine AI Avatar" in June 2025, and by August, it had released 10 AI avatars covering eight core specialties in traditional Chinese medicine, enhancing the supply of quality medical services [2]

Group 1 - The AI healthcare sector is in the early stages of commercialization but has attracted significant investment from public QDII funds, with a focus on overseas markets for growth opportunities [1][5] - Major public funds such as Huaxia, CMB, and GF have heavily invested in Hong Kong-listed AI healthcare companies like Jingtai Holdings and Yidu Tech, which are expanding into international markets through technology exports and acquisitions [1][5] - Companies like Jingtai Holdings and Yidu Tech have reported strong overseas revenue growth, with Yidu Tech's revenue from Brunei contributing 14.36% to its total [1][5] Group 2 - Despite the enthusiasm, there are concerns about high valuations in the Hong Kong AI healthcare sector, with price-to-sales ratios reaching tens or even hundreds, leading some funds to shift focus to more reasonably valued US stocks [2][4] - The market is witnessing a valuation discrepancy, as seen with Mirxes, which has a market cap exceeding HKD 17 billion, while its US competitor Grail, with significantly higher revenue, has a lower market cap [4] - Fund managers express optimism about the commercialization prospects of domestic AI healthcare, believing that accelerating commercialization will address current high valuation concerns [4][5] Group 3 - The formation of a commercial loop in overseas AI healthcare, particularly in brain-computer interface technology, is expected to lead to clinical applications within 1-2 years and commercialization within 3-5 years, significantly expanding market potential [5]